Prescient Therapeutics reaches a major CAR-T manufacturing milestone


  • Prescient Therapeutics has completed the manufacturing and delivery of crucial components for its unique next-generation OmniCAR platform.
  • The production of binders for various cancer targets will enable Prescient’s research team to manufacture CAR-T cells for its three next-generation CAR-T programs.
  • The oncology firm has also obtained delivery of lentiviral vectors to manufacture CAR-T cells expressing SpyCatcher.
  • Prescient has developed OmniCAR as a platform that offers collaborations and third-party licensing opportunities.

In a milestone development regarding its innovative CAR-T cancer therapy programs, Prescient Therapeutics Limited (ASX:PTX) has announced that it has successfully completed the manufacturing and delivery of crucial components for its unique, next-generation OmniCAR platform.

The two novel components of the OmniCAR platform are: the SpyTagged binders and CAR-T cells expressing SpyCatcher. Notably, the SpyTag/SpyCatcher system is a crucial technology for binding of proteins. SpyCatcher is a genetically encoded protein, which reacts with SpyTag, a peptide of 13 amino acids, forming a bond between the two.

WATCH NOW: Expert Talks With Mr Steven Yatomi Clarke, CEO and Managing Director of Prescient Therapeutics

Delivery of binders and lentiviral vectors

The Company disclosed that a range of binders against various cancer targets, including CLL-1, CD33, EGFRviii, and Her2, have been manufactured by a US-based antibody manufacturer. More importantly, Prescient has incorporated SpyTag into these binders for the Company’s three next-gen CAR-T programs. SpyTag is necessary for covalent binding to immune cells (for instance, T-cells) in the OmniCAR system.

ALSO READ: Prescient Therapeutics’ major strides in anti-cancer programs set the stage for a sturdy 2021

Source: PTX Update, 24 June 2021

Besides binders, Prescient has also obtained the delivery of lentiviral vectors. Lentiviral vectors are viruses which are used as gene delivery vehicle as they help in inserting, tweaking, or deleting a particular gene in a cell or organism.

As highlighted by PTX, lentiviral vectors are a rate-limiting step in CAR-T production and will be used to produce CAR-T cells expressing SpyCatcher.

Together, the SpyTagged binders and SpyCatcher CAR-T cells establish the basis for Prescient’s unique, modular OmniCAR platform.

The binders and lentiviral vectors have been delivered to the Peter MacCallum Cancer Centre, or Peter Mac, in Melbourne for construct assessment as well as in vivo and in vitro development.

DO READ: Prescient Therapeutics inks new deal with Peter Mac to rev up its OmniCAR programs

How does Prescient’s OmniCAR work?

Prescient is developing OmniCAR programs for acute myeloid leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma (GBM) multiforme, the most widespread form of brain carcinoma.

MUST READ: Get Acquainted with Prescient Therapeutics’ Next Generation Immunotherapy Platform

After the formation of a fully armed and activated CAR-T cell, the cell activity can be controlled, and its target specificity can be switched when necessary.

Source: PTX Update, 24 June 2021

Additionally, Prescient has developed OmniCAR as a platform that permits collaborations and partnerships under licence with third parties willing to incorporate OmniCAR to improve their respective cell therapies.

The OmniCAR platform is developed based on technologies established at the University of Pennsylvania and the University of Oxford. Notably, the Company has secured global licensing rights for the commercialisation of those technologies.

Investor Briefing: The Company will host a briefing for PTX shareholders and investors on 1 July 2021 at 11:00 AM AEST. The event would discuss the progress with OmniCAR programs and the Peter Mac partnership.

To register for the event, click here.

Management Commentary

Steven Yatomi-Clarke, the CEO and Managing Director of Prescient, commented-

Mr Steven also added that the research team of Prescient at Peter Mac had completed all the preparatory work in parallel. Besides, the delivery of the binders and vectors now empowers the team to progress the Company’s in-house next-generation cell therapies.

ALSO READ: A year of transformation and continuing to forge ahead: Prescient Therapeutics ticks all right boxes in 2020

On 24 June 2021, PTX shares last traded at AU$0.200.

To know more about Prescient Therapeutics Limited, click here.

To stay updated with PTX company activities and announcements, please update your details on their investor centre.

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.



Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK